The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 April 2026•

1 min read

Nuvalent Submits FDA New Drug Application for Neladalkib in ALK-positive Lung Cancer

Key Facts

1Nuvalent announced the submission of a New Drug Application (NDA) to the U.S. FDA for neladalkib.

2The drug targets patients with TKI pre-treated advanced ALK-positive non-small cell lung cancer (NSCLC).

Nuvalent, Inc. (NUVL) has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug, neladalkib. The drug is designed to treat patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have previously undergone treatment with tyrosine kinase inhibitors (TKIs). This regulatory submission is supported by clinical data from the global ALKOVE-1 Phase 1/2 trial, which evaluated the efficacy and safety of the ALK-selective inhibitor. The move marks a critical milestone for the clinical-stage biotech company as it transitions toward potential commercialization. Market analysts view this development as a significant de-risking event for Nuvalent's lead candidate. If approved, neladalkib could provide a new therapeutic option for a patient population with high unmet medical needs.